Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.53 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.53 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.53 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.50 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.50 |
| ▸ | CPT2 | P23786 | 1/20 | 0.47 |
| ▸ | CPT1A | P50416 | 1/20 | 0.47 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20734548 | 1.00 | FAAH (0.71) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL9509876 | 0.98 | FAAH (0.68) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL10437118 | 0.92 | FAAH (0.59) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL277126 | 0.83 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL20143550 | 0.83 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL4023787 | 0.83 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| Hexadecanoic Acid Isopropylamide SCHEMBL1457147 | 0.83 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL2146114 | 0.83 | FAAH (0.77) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL12459875 | 0.83 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL1456463 | 0.83 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0912730-B1 | CONJUGATES OF SOLUBLE PEPTIDIC COMPOUNDS WITH MEMBRANE-BINDING AGENTS | ADPROTECH LTD (GB) | 2008-12-31 | — | — | EP | claimed |
| EP-1097198-A2 | SOLUBLE DERIVATIVES OF ANTI-ANGIOGENIC PEPTIDES | AdProTech plc (GB) | 2001-05-09 | — | — | EP | claimed |
| WO-2000004052-A2 | SOLUBLE DERIVATIVES OF ANTI-ANGIOGENIC PEPTIDES | ADPROTECH LIMITED (GB) | 2000-01-27 | — | — | WO | claimed |
| CN-114651014-A | IL-15 fusion peptides for the treatment of cancer | 前列腺癌研究中心 | 2022-06-21 | — | — | CN | disclosed |
| US-20110086808-A1 | MODIFIED THERAPEUTIC AGENTS | ADPROTECH LIMITED (GB) | 2011-04-14 | — | — | US | disclosed |
| US-7655617-B2 | Conjugates of soluble peptidic compounds with membrane-binding agents | ADPROTECH LIMITED (GB) | 2010-02-02 | — | — | US | disclosed |
| EP-0912730-B1 | CONJUGATES OF SOLUBLE PEPTIDIC COMPOUNDS WITH MEMBRANE-BINDING AGENTS | ADPROTECH LTD (GB) | 2008-12-31 | — | — | EP | disclosed |
| EP-0979276-B1 | COMPLEMENT RECEPTOR TYPE 1 (CR1)-LIKE SEQUENCES | ADPROTECH LTD (GB) | 2006-12-13 | — | — | EP | disclosed |
| US-20060241048-A1 | Modified therapeutic agents | ADPRO TECH LIMITED (GB) | 2006-10-26 | — | — | US | disclosed |
| EP-1542730-B1 | MODIFIED THERAPEUTIC AGENTS | ADPROTECH LTD (GB) | 2006-06-07 | — | — | EP | disclosed |
| EP-1542730-A1 | MODIFIED THERAPEUTIC AGENTS | AdProTech Limited (GB) | 2005-06-22 | — | — | EP | disclosed |
| US-20040266684-A1 | Conjugates of soluble peptidic compounds with membrane-binding agents | ADPROTECH LIMITED (GB) | 2004-12-30 | — | — | US | disclosed |
| US-6713606-B1 | THERAPEUTIC AGENT BOUND VIA LINKER TO A HYDROPHILIC PEPTIDE BINDING ELEMENT OF THE MEMBRANE LOCALIZATION REAGENT TO FORM THE SOLUBLE COMPOUND | ADPROTECH LIMITED (GB) | 2004-03-30 | — | — | US | disclosed |
| WO-2004022101-A1 | MODIFIED THERAPEUTIC AGENTS | ADPROTECH LIMITED (GB) | 2004-03-18 | — | — | WO | disclosed |
| US-20030064431-A1 | COMPLEMENT RECEPTOR TYPE 1 (CR1)-LIKE SEQUENCES | ADPROTECH LIMITED (GB) | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266684-A1 | Conjugates of soluble peptidic compounds with membrane-binding agents | SELPLG, CD2BP2, EPCAM | FAAH 3274/4885MEN1 911/4885KMT2A 4177/4885 |
| US-20030064431-A1 | COMPLEMENT RECEPTOR TYPE 1 (CR1)-LIKE SEQUENCES | LHCGR, FSHR, C3AR1 | FAAH 4395/4885MEN1 1212/4885KMT2A 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.